Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVENT-NEURO
NCT06819592Phase 3Recruiting
- Sponsor
- The George Institute for Global Health
- Start
- Oct 2025
- Primary completion
- Aug 2029
- Modality
- Reversible Covalent Inhibitors
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in ventilator-associated pneumonia (VAP) and lower respiratory tract infection (LRTI) comparing Ceftriaxone injection with Placebo (2 arms). Primary endpoint: All cause mortality at 90 days. Started Oct 2025; status: recruiting.
02
Drugs
ceftriaxone
03
Conditions
ventilator-associated pneumonia (VAP)lower respiratory tract infection (LRTI)
Beyond the preview
Go deeper on NCT06819592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06819592.